Hint mode is switched on Switch off

Exelixis, ordinary share
US30161Q1040, EXEL

Add a stock to WL
Choose all Reset all
Exelixis, сountry — USA
No trading data
Data display in a chart | table
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
Source of information - PJSC "MOEX". Further disctribution of MOEX information is prohibited without prior consent with PJSC "MOEX".
from
to
ADD-IN
Cbonds add-in API
bond data api
Authorization required
You need to request access
More than 2,500 records have been found, please specify your request
No data for the selected period

explore the most comprehensive database

900 000

bonds globally

Over 400

pricing sources

80 000

stocks

116 000

ETF & Funds

track your portfolio in the most efficient way

  • Bond Search
  • Watchlist
  • Excel ADD-IN
Get access
×

— Are you looking for the complete & verified bond data?

— We have everything you need:

full data on over 900 000 bonds, 80 000 stocks, 116 000 ETF & Funds; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; user-friendly interface; available anywhere via Website, Excel Add-in and Mobile app.

Register
×

Why

You will have detailed descriptive & pricing data for 650K bonds, 76K stocks, 8K ETFs
Get full access to the platform from any device & via Cbonds app
Enhance your portfolio management with Cbonds Excel Add-in
Build yield maps, make chart comparison within a click
Don't wait any longer — start using Cbonds today! Register

Latest quotes

Analysts forecasts

Issuer

Profile
Exelixis, Inc. (Exelixis) is a biotechnology company engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing its resources and development efforts on cabozantinib (XL184). It also has a portfolio of ...
Exelixis, Inc. (Exelixis) is a biotechnology company engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing its resources and development efforts on cabozantinib (XL184). It also has a portfolio of other compounds. Cabozantinib is the inhibitor of MET in clinical development and is being evaluated in a development program encompassing multiple cancer indications. 
Show more Hide
  • Issuer
  • Full borrower / issuer name
    Exelixis, Inc
  • Industry
    Pharmaceutical Preparation and Biotechnology

Placement data

  • Placement type
    IPO | Finished
  • Subscription type
    Open
  • Placement exchange
    NASDAQ
  • Ticker
    EXEL
  • Placement
    11.04.2000
  • Lock up period
    180
  • Number of papers
    9,100,000
  • Volume of raised funds
    118.3 mln USD
  • Placement share
    21%
  • Final placement price
    13 USD
  • Price change since placement date
    210.54%
  • By capitalization
    555.95 mln USD

IFRS/US GAAP reports

2025
I q eng
2024
I q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
I q eng
II q eng
III q eng
IV q eng
2016
I q eng
II q eng
III q eng
IV q eng
2015
I q eng
II q eng
III q eng
IV q eng
2014
IV q eng
Show all Hide

Related Stock indices

Indicators

News

28/05/2025 Exelixis: Submission Of Matters To A Vote Of Security Holders
13/05/2025 Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update
20/02/2025 Exelixis: Other Events, Financial Statements And Exhibits
11/02/2025 Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update
28/01/2025 Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
All organization news

Other stocks and deposit receipts

Holders

Industry Leaders

Registration is required to get access.